Announced Fri, 29 May · 14:19 IST

Outcome of Board Meeting held on 29.05.2026

Revenue Growth 20pctPat Growth 25pctResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-9.6%1-day move
₹85.95
prior close
₹86.21
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.5+1.5+1.5-1.4-9.6-10.5-10.6-9.9-9.5-8.7-5.8-6.5
Up moveDown movePending
AI summary

Jeevan Scientific Technology Limited reported strong FY2026 results with standalone revenue growing 23.7% to Rs 5,393 lakhs and consolidated revenue up 31.3% to Rs 6,154 lakhs. Standalone profit after tax jumped 124% to Rs 165 lakhs, while consolidated PAT rose significantly from Rs 5.9 lakhs to Rs 103 lakhs. The Board approved audited results with an unmodified audit opinion from Pavuluri & Co. Additionally, 480,000 new stock options were granted to employees under the JSTL ESOP Scheme 2016, and 161,250 equity shares were allotted to employees who exercised their options at Rs 10 per share. M/s KP & Associates was appointed as internal auditors for FY2026-27. The company's paid-up capital increased to Rs 19.92 crore after the ESOP allotment.

Likely market impact

The company showed robust revenue and profit growth, and the clean audit opinion with no qualifications provides confidence to shareholders. ESOP grants align employee interests with shareholders while the share allotment has a modest dilutive effect.